AMENDED AND RESTATED LICENSE AND COMMERCIALIZATION AGREEMENT BY AND AMONG IKARIA DEVELOPMENT SUBSIDIARY ONE LLC AND BIOLINERX LTD. AND BIOLINE INNOVATIONS JERUSALEM L.P.License and Commercialization Agreement • March 31st, 2015 • Bellerophon Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated License and Commercialization Agreement (the “Agreement”) is entered into this 26th day of August, 2009, by and among Ikaria Development Subsidiary One LLC, a Delaware limited liability company having a principal place of business at 6 State Route 173, Clinton, NJ 08809, USA (“Ikaria”), BioLineRx Ltd., a corporation organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLineRx Ltd.”), and BioLine Innovations Jerusalem L.P., a limited partnership organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLine Innovations”; together with BioLineRx Ltd., “BioLineRx”).
TEXT OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(B)(4) AND 240.24B-2. AMENDMENT NO. FOUR TO LICENSE AND COMMERCIALIZATION AGREEMENT This AMENDMENT NO. FOUR...License and Commercialization Agreement • March 16th, 2006 • Valeant Pharmaceuticals International • Pharmaceutical preparations • California
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • July 1st, 2011 • BioLineRx Ltd. • Pharmaceutical preparations • New York
This Amended and Restated License and Commercialization Agreement (the “Agreement”) is entered into this 26th day of August, 2009, by and among Ikaria Development Subsidiary One LLC, a Delaware limited liability company having a principal place of business at 6 State Route 173, Clinton, NJ 08809, USA (“Ikaria”), BioLineRx Ltd., a corporation organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLineRx Ltd.”), and BioLine Innovations Jerusalem L.P., a limited partnership organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLine Innovations”; together with BioLineRx Ltd., “BioLineRx”).
AMENDMENT NO. 1 TO LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • August 6th, 2020 • Harmony Biosciences Holdings, Inc. • Pharmaceutical preparations • England and Wales
This Amendment No. 1, dated as of August 27, 2018 (this “Amendment”), to the License and Commercialization Agreement (the “Agreement”), dated as of July 28, 2017, is entered into between Bioprojet Societe Civile de Recherche, an independent (privately) owned research company organized under the laws of France and having its principal place of business at 30, rue des Francs-Bourgeois, 75003 Paris, France (“Bioprojet SCR”) and together with its Affiliates, including Bioprojet Pharma SARL and Bioprojet Europe Ltd., “Bioprojet”), and Harmony Biosciences, LLC, a limited liability company organized under the laws of Delaware and having its principal place of business at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania 19462 USA (“Partner”). Capitalized terms used, but not otherwise defined, in this Amendment shall have the meanings ascribed to them in the Agreement. Bioprojet and Partner may be referred to herein, together, as the “Parties” and, individually, as a “Party.”
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • January 28th, 2010 • Alr Technologies Inc • Communications equipment, nec • Virginia
This License and Commercialization Agreement (“Agreement”) is made as of September 11, 2009 (the “Effective Date”), by and between ALR TECHNOLOGIES, INC., a Nevada corporation having its principal office at 3350 Riverwood Pkwy., Suite 1900, Atlanta, Georgia 30339 (“ALRT”), and PARI RESPIRATORY EQUIPMENT, INC., a Delaware corporation having its principal office at 2943 Oak Lake Boulevard, Midlothian, Virginia 23112 (“PARI”).
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • May 5th, 2020 • New York
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of the signature date of the contract (the “Effective Date”) by and between:
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • January 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations • Hong Kong
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”), dated as of March 20, 2023 (“Effective Date”), is entered into by and between APRINOIA Therapeutics Inc., a company duly organized under the laws of Japan, having its place of business at Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan (“APN JP”), APRINOIA Therapeutics Inc., a company incorporated under the laws of the Cayman Islands, with its registered office at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (“APN Cayman”), Yantai Yitai Pharmaceutical Technology Co., Ltd., a company duly organized under the laws of the People’s Republic of China, having its place of business at Room 101, Block 52, No. 500, East Bin Hai Rd., Mu Ping District, Yan Tai, Shandong Province, PRC (“Yitai”), and Yantai Dongcheng Pharmaceutical Group Co., Ltd., a company duly organized under the laws of the People’s Republic of China, having its place of business at No.7, Changbai Mountain Rd., Economic and Technological Development
AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • July 1st, 2011 • BioLineRx Ltd. • Pharmaceutical preparations
This Amendment (this “Amendment”) is entered into this 21st day of April 2010 (the “Amendment Effective Date”) by and between Ikaria Development Subsidiary One LLC, a Delaware limited liability company with a place of business at 6 Route 173, Clinton, NJ, 08809 USA (“Ikaria”), and BiolineRx Ltd., a corporation organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLineRx Ltd.”), and BioLine Innovations Jerusalem L.P., a limited partnership organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158 Jerusalem 91450, Israel (“BioLine Innovations”; together with BioLineRx Ltd., “BioLine Rx”) . This Amendment amends the Amended and Restated License and Commercialization Agreement entered into by and between Ikaria and BioLineRx dated as of the 26th day of August 2009 (the “Agreement”). Any defined term
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. LICENSE AND...License and Commercialization Agreement • August 6th, 2020 • Harmony Biosciences Holdings, Inc. • Pharmaceutical preparations • England and Wales
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”) dated as of July 28, 2017 (“Signing Date”) is entered into between Bioprojet Société Civile de Recherche, an independent (privately owned) research company organized under the laws of France and having its principal place of business at 30, rue des Francs-Bourgeois, 75003 Paris, France (“Bioprojet SCR” and together with its Affiliates, including Bioprojet Pharma SARL and Bioprojet Europe Ltd., “Bioprojet”) and Harmony Biosciences, LLC, a limited liability company organized under the laws of Delaware and having its principal place of business at 1033 Skokie Boulevard, Suite 600, Northbrook, Illinois 60062 (“Partner”).
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • October 9th, 2018 • CareDx, Inc. • Services-medical laboratories • California
This License and Commercialization Agreement (“Agreement”) is effective as of the date of last signature below (the “Effective Date”) by and between Illumina, Inc., a Delaware corporation, having a place of business at 5200 Illumina Way, San Diego, CA, 92122 (“Illumina”), and CareDx, Inc., a Delaware corporation, having a place of business at 3260 Bayshore Boulevard, Brisbane, CA 94005 (“CareDx”). Illumina and CareDx may each be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. AMENDMENT No. 1 TO LICENSE AND...License and Commercialization Agreement • May 16th, 2022 • Petros Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) to the License and Commercialization Agreement dated as of September 30, 2016, is hereby entered into and effective as of January 18, 2022 (the “Amendment Effective Date”) by and between VIVUS LLC, a Delaware limited liability company, (“VIVUS”), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”). VIVUS and Metuchen are sometimes referred to in this Amendment collectively as the “Parties” and individually as a “Party”.
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • July 11th, 2014 • Otonomy, Inc. • Pharmaceutical preparations • California
Each of the above milestones shall be payable once only and only for the first occurrence of each such milestone, irrespective of the number of Licensed Products that may achieve such milestone, and only to the extent the Licensed Product triggering such milestone is Covered by a Valid Claim in the country in which the applicable filing or approval occurs.
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • April 14th, 2014 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
This License and Commercialization Agreement (the “Agreement”) is hereby entered into and effective as of November 21, 2005 (the “Effective Date”) by and between IntelliPharmaCeutics Corp. ("IPC"), a Nova Scotia corporation, with offices located at 30 Worcester Road, Toronto, Ontario, Canada and Par Pharmaceutical, Inc. (“Par”), a Delaware corporation with offices located at 300 Tice Boulevard, Woodcliff Lake, New Jersey 07677, USA. IPC and Par shall each be defined as a “Party” and together as the “Parties” under this Agreement.
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this...License and Commercialization Agreement • June 27th, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances) • Delaware
This LICENSE AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is made as of June 14, 2022 (the “Effective Date”) by and between RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (“Romeg”), and Scilex Holding Company (“Licensee”). Romeg and Licensee are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.”
TO LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • April 30th, 2024 • Harmony Biosciences Holdings, Inc. • Pharmaceutical preparations
This Amendment No. 2, dated as of April 6, 2024 (this “Second Amendment”), to the License and Commercialization Agreement, dated as of July 28, 2017, and amended on August 27, 2018 (the “First Amendment”, collectively the “Agreement”), is entered into between Bioprojet Société Civile de Recherche, an independent (privately) owned research company organized under the laws of France and having its principal place of business at 30, rue des Francs-Bourgeois, 75003 Paris, France (“Bioprojet SCR”) and together with its Affiliates, including Bioprojet Pharma SARL and Bioprojet Europe Ltd., “Bioprojet”), and Harmony Biosciences, LLC, a limited liability company organized under the laws of Delaware and having its principal place of business at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania 19462 USA (“Partner”). Capitalized terms used, but not otherwise defined, in this Second Amendment shall have the meanings ascribed to them in the Agreement. Bioprojet and Partner may be r
LICENSE AND COMMERCIALIZATION AGREEMENT by and between VIVUS, INC. and SANOFILicense and Commercialization Agreement • February 28th, 2014 • Vivus Inc • Pharmaceutical preparations • New York
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of the 11th day of December, 2013 (the “Effective Date”) by and between Vivus, Inc., a corporation with its principal office at 351 E. Evelyn Avenue, California, 94041, United States of America (referred to herein as “Vivus”), and Sanofi, a French corporation having a place of business at 54 rue la Boétie, 75008, Paris, France (referred to herein as “Sanofi”). Vivus and Sanofi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...License and Commercialization Agreement • May 14th, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations
Reference is made to the License and Commercialization Agreement effective as of November 21, 2006, as amended (the “Agreement”) between Medarex, Inc., now a wholly-owned subsidiary of Bristol-Myers Squibb Company (“BMS”) and BioTie Therapies Corporation (“BioTie”).
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • August 4th, 2004 • Durect Corp • Pharmaceutical preparations • California
THIS LICENSE AND COMMERCIALIZATION AGREEMENT including the exhibits referred to herein and attached hereto which are hereby incorporated by reference (the “Agreement”), entered into as of May 13, 2004, by and between NeuroSystec Corporation, a Delaware corporation having a principal place of business located at Mann Biomedical Park, 25134 Rye Canyon Loop, Suite 370, Valencia, CA 91355 (“NeuroSystec”) and DURECT Corporation, a Delaware corporation having a principal place of business located at 10240 Bubb Road, Cupertino, California 95104 (“DURECT”).
AMENDED AND RESTATED LICENSE AND COMMERCIALIZATION AGREEMENT between GENMAB A/S and TENX BIOPHARMA, INC. Dated as of December 22, 2009License and Commercialization Agreement • August 5th, 2011 • Emergent BioSolutions Inc. • Pharmaceutical preparations • New York
LICENSE AND COMMERCIALIZATION AGREEMENT dated as of September 30, 2016 by and between VIVUS, INC. and METUCHEN PHARMACEUTICALS LLCLicense and Commercialization Agreement • October 21st, 2020 • Petros Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is dated as of the 30th day of September, 2016, by and between VIVUS, INC., a Delaware corporation having its principal offices at 351 E. Evelyn Ave., Mountain View, CA 94041 (“VIVUS”), and Metuchen Pharmaceuticals LLC, a limited liability company organized under the laws of Delaware, having a place of business at 11 Commerce Drive, 1st Floor, Cranford, New Jersey 07016 (“Licensee”). VIVUS and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • April 13th, 2023 • ACELYRIN, Inc. • Pharmaceutical preparations
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”) dated as of March 25, 2021 (“Effective Date”) is entered into between Pierre Fabre Medicament SAS, a company duly organized and existing under the laws of France, having offices and principal place of business at 45, Place Abel Gance 92100 Boulogne Billancourt, France (“Licensor”) and ValenzaBio Inc., a limited liability company organized under the laws of Delaware and having its principal place of business at 6701 Democracy Blvd, Suite 300, Bethesda, MD 20817 (“Licensee”).
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • March 23rd, 2015 • BioLineRx Ltd. • Pharmaceutical preparations • New York
This Amended and Restated License and Commercialization Agreement (the “Agreement”) is entered into this 26th day of August, 2009, by and among Ikaria Development Subsidiary One LLC, a Delaware limited liability company having a principal place of business at 6 State Route 173, Clinton, NJ 08809, USA (“Ikaria”), BioLineRx Ltd., a corporation organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLineRx Ltd.”), and BioLine Innovations Jerusalem L.P., a limited partnership organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLine Innovations”; together with BioLineRx Ltd., “BioLineRx”).
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • November 1st, 2022 • Harmony Biosciences Holdings, Inc. • Pharmaceutical preparations • England and Wales
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”) dated as of July 31, 2022 (“Signing Date”) is entered into between Bioprojet Société Civile de Recherche, an independent (privately owned) research company organized under the laws of France and having its principal place of business at 30, rue des Francs-Bourgeois, 75003 Paris, France (together with its Affiliates, including Bioprojet Pharma SAS and Bioprojet Europe Ltd., “Bioprojet”) and Harmony Biosciences, LLC, a limited liability company organized under the laws of Delaware and having its principal place of business at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania, USA (“Harmony”).
TO LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • April 30th, 2024 • Harmony Biosciences Holdings, Inc. • Pharmaceutical preparations
This Amendment No. 1, dated as of April 6, 2024 (this “First Amendment”), to the License and Commercialization Agreement, dated as of July 31, 2022, (the “Agreement”), is entered into between Bioprojet Société Civile de Recherche, an independent (privately) owned research company organized under the laws of France and having its principal place of business at 30, rue des Francs-Bourgeois, 75003 Paris, France (together with its Affiliates, including Bioprojet Pharma SAS and Bioprojet Europe Ltd., “Bioprojet”), and Harmony Biosciences, LLC, a limited liability company organized under the laws of Delaware and having its principal place of business at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania 19462 USA (“Partner”). Capitalized terms used, but not otherwise defined, in this First Amendment shall have the meanings ascribed to them in the Agreement. Bioprojet and Partner may be referred to herein, together, as the “Parties” and, individually, as a “Party.”
AMENDMENT NO. 1 TO LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • May 14th, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO LICENSE AND COMMERCIALIZATION AGREEMENT (“Amendment No. 1”) is made and entered into effective as of June 13, 2007, (the “Amendment No. 1 Date”) by and between, on the one hand, BIOTIE THERAPIES CORP. (“BioTie”) and, on the other hand, MEDAREX, INC. and GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc., (together “Medarex”), each being referred to herein as a “Party” and together, the “Parties.”
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • November 9th, 2016 • Vivus Inc • Pharmaceutical preparations • New York
*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
CONFIDENTIAL TREATMENT REQUESTED LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • March 15th, 2018 • Histogenics Corp • Orthopedic, prosthetic & surgical appliances & supplies • New York
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is effective as of 21st December, 2017 (the “Effective Date”) by and between Histogenics Corporation., a corporation organized and existing under the laws of the State of Delaware, with offices at 830 Winter Street, 3rd Floor, Waltham, MA, 02451 (“Histogenics”), and MEDINET Co., Ltd., a corporation organized and existing under the laws of Japan, with offices at 2-3-12 Shinyokohama, Kohoku-ku, Yokohama-shi, Kanagawa-ken, Japan (“MEDINET”) (each, a “Party” and together, the “Parties”).
LICENSE AND COMMERCIALIZATION AGREEMENT by and between VIVUS, INC. and BERLIN- CHEMIE AGLicense and Commercialization Agreement • August 8th, 2013 • Vivus Inc • Pharmaceutical preparations • California
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is executed on the 5th of July, 2013 (the “Execution Date”) by and between VIVUS, INC., a Delaware corporation with its principal place of business at 351 E. Evelyn Avenue, Mountain View, CA 94041, United States (“VIVUS”), and BERLIN-CHEMIE AG, a German public limited company having a place of business at Glienicker Weg 125 — 127, 12489 Berlin, Germany (“Menarini”). VIVUS and Menarini are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN AMGEN INC. AND INTERMUNE, INC. June 15, 2001License and Commercialization Agreement • August 3rd, 2001 • Intermune Inc • Pharmaceutical preparations • California
This License and Commercialization Agreement (the "Agreement") is made effective as of the 15th day of June, 2001 (the "Effective Date") by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799 ("Amgen") and InterMune, Inc., a Delaware corporation having its principal place of business at 1710 Gilbreth Road, Suite 310, Burlingame, CA 94010-1317 ("InterMune"). Amgen and InterMune are sometimes referred to herein individually as a "Party" and collectively as the "Parties", and references to "InterMune" and "Amgen" shall include their respective Affiliates.
LICENSE AND COMMERCIALIZATION AGREEMENT dated as of October 10, 2013 by and between VIVUS, INC. and AUXILIUM PHARMACEUTICALS, INC.License and Commercialization Agreement • November 7th, 2013 • Vivus Inc • Pharmaceutical preparations • New York
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of the 10th day of October 2013 (the “Effective Date”) by and between VIVUS, INC., a Delaware corporation having its principal offices at 351 E. Evelyn Ave., Mountain View, CA 94041 (“VIVUS”), and AUXILIUM PHARMACEUTICALS, INC., a Delaware corporation having a place of business at 640 Lee Road, Chesterbrook, PA 19087. (“Auxilium”). VIVUS and Auxilium are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • June 20th, 2024 • Nuvation Bio Inc. • Pharmaceutical preparations
This License and Commercialization Agreement (this “Agreement”), dated October 27th, 2023 (the “Effective Date”), is entered into by and between: AnHeart Therapeutics Inc., a Delaware corporation having its office and place of business at 777 3rd avenue, New York, NY 10017, USA (“AnHeart”); and Nippon Kayaku Co., Ltd., a Japanese corporation having its office and place of business at 1-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo 100-0005, Japan (“NK”). AnHeart and NK are each referred to herein by name, individually as a “Party”, or collectively as the “Parties”.
AMENDMENT NO. 1 TO LICENSE AND COMMERCIALIZATION AGREEMENT AND COMMERCIAL SUPPLY AGREEMENTLicense and Commercialization Agreement • August 6th, 2019 • Vivus Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO LICENSE AND COMMERCIALIZATION AGREEMENT AND COMMERCIAL SUPPLY AGREEMENT (the “Amendment”) is effective as of the 1st day of January, 2019 (the “Amendment Effective Date”) by and between VIVUS, INC., a Delaware corporation with its principal place of business at 900 E. Hamilton Avenue, Suite 550, Campbell, CA 95008, United States (“VIVUS”), and BERLIN-CHEMIE AG, a German public limited company having a place of business at Glienicker Weg 125 – 127, 12489 Berlin, Germany (“Menarini”). VIVUS and Menarini are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Amendment No. Three to License and Commercialization AgreementLicense and Commercialization Agreement • March 16th, 2005 • Intermune Inc • Pharmaceutical preparations
This AMENDMENT NO. THREE TO LICENSE AND COMMERCIALIZATION AGREEMENT (the “Amendment No. Three”) is made effective as of December 31, 2004 (the “Amendment Effective Date”), and is entered into by and between AMGEN INC., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (“Amgen”) and INTERMUNE, INC., a Delaware corporation having its principal place of business at 3280 Bayshore Blvd., Brisbane, CA 94005 (“InterMune”). Amgen and InterMune are sometimes referred to herein individually as a “Party” and collectively as the “Parties,” and references to “InterMune” and “Amgen” shall include their respective Affiliates. All capitalized terms used herein shall have the meaning given to them in the Original Agreement (as defined below) unless otherwise defined herein.
Amendment No. 1 to Amgen/InterMune License and Commercialization Agreement for Infergen Dear Mr. Crawford:License and Commercialization Agreement • August 13th, 2002 • Intermune Inc • Pharmaceutical preparations • California
Our signatures below approve this document as Amendment No. 1 ("Amendment") to that certain License and Commercialization Agreement, dated as of June 15, 2001, between Amgen Inc. ("Amgen") and InterMune, Inc. ("InterMune") (the "Agreement"). Amgen and InterMune shall be collectively referenced herein as the "Parties."
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • November 7th, 2016 • Dubuc Motors Inc. • Delaware
NOW THEREFORE in consideration of the mutual covenants and conditions contained herein, the receipt and sufficiency of which is acknowledged by the parties, the parties hereto agree as follows:
